Immunotherapy in lung cancer: the chemotherapy conundrum

Chin Clin Oncol. 2020 Aug;9(4):59. doi: 10.21037/cco.2020.01.05. Epub 2020 Feb 4.

Authors

Laxmi Narayana R Buddharaju¹, Apar Kishor Ganti²

Affiliations

¹ Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
² Division of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; Division of Oncology-Hematology, Department of Internal Medicine, VA-Nebraska, Western Iowa Health Care System, Omaha, NE, USA. aganti@unmc.edu.

PMID: 32036674
DOI: 10.21037/cco.2020.01.05

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung*
Humans
Immunotherapy
Lung Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
B7-H1 Antigen
pembrolizumab